期刊
ONCOTARGET
卷 8, 期 44, 页码 78174-78192出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.19836
关键词
melanoma; BRAF; MAPK; immunotherapy; CTLA-4
资金
- Medical Research Council [MR/L023091/1]
- Cancer Research UK [C30122/A11527, C30122/A157745]
- Academy of Medical Sciences
- Breast Cancer Now [147]
- CR UK/NIHR in England/DoH for Scotland
- Wales and Northern Ireland Experimental Cancer Medicine Centre [C10355/A15587]
- British Skin Foundation [S633]
- British Association of Dermatologists
- Dermatrust
- Guy's and St Thomas's Charity Melanoma Special Fund
- National Institute for Health Research (NIHR) BRC based at Guy's and St Thomas' NHS Foundation Trust and King's College London [ISBRC-1215-20006]
- Academy of Medical Sciences (AMS) [AMS-SGCL10-Josephs, AMS-SGCL6-Papa] Funding Source: researchfish
- Medical Research Council [MR/L006278/1, MR/L023091/1] Funding Source: researchfish
- National Institute for Health Research [CL-2011-17-007, CL-2012-17-005] Funding Source: researchfish
- MRC [MR/L006278/1, MR/L023091/1] Funding Source: UKRI
Identification of mutations in the gene encoding the serine/threonine-protein kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in around 50% of malignant melanomas have led to the development and regulatory approval of targeted pathway inhibitor drugs. A proportion of patients are intrinsically resistant to BRAF inhibitors, and most patients who initially respond, acquire resistance within months. In this review, we discuss pathway inhibitors and their mechanisms of resistance, and we focus on numerous efforts to improve clinical benefits through combining agents with disparate modes of action, including combinations with checkpoint inhibitor antibodies. We discuss the merits of combination strategies based on enhancing immune responses or overcoming tumor-associated immune escape mechanisms. Emerging insights into mechanisms of action, resistance pathways and their impact on host-tumor relationships will inform the design of optimal combinations therapies to improve outcomes for patients who currently do not benefit from recent treatment breakthroughs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据